Opus Genetics, Inc. Income Statement
IRD|7 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Opus Genetics, Inc. reported $11M in revenue and $58M in net loss for FY2025. Revenue has grown at a 165.2% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2013 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.0M | $19.0M | $39.9M | $589.0K | $0 | $0 | $0 |
| SG&A Expense | $18.2M | $12.0M | $7.3M | $8.1M | $2.8M | $2.7M | $2.9M |
| R&D Expense | $26.9M | $17.7M | $14.4M | $15.2M | $6.6M | $3.4M | $3.2M |
| Operating Income | -$62.1M | -$10.6M | $18.2M | -$22.7M | -$20.0M | -$6.6M | -$6.5M |
| Interest Expense | - | - | $9.0K | $2.0K | $6.8M | - | - |
| Income Tax | $0 | $12.0K | $315.0K | $0 | $0 | $0 | $0 |
| Net Income | -$57.5M | -$10.0M | $17.9M | -$56.7M | -$24.6M | -$625.1K | -$2.9M |
| EPS (Basic) | -$2.15 | -$0.46 | $0.90 | -$3.82 | -$5.28 | - | - |
| EPS (Diluted) | -$2.15 | -$0.46 | $0.87 | -$3.82 | -$5.28 | -$0.06 | -$0.05 |
| Shares Outstanding | 31.6M | 24.0M | 20.9M | 18.8M | 10.9M | 119.4M | 84.2M |
| Operating Margin | -564.7% | -55.5% | 45.7% | -3854.8% | - | - | - |
| Profit Margin | -523.4% | -52.4% | 44.9% | -9625.3% | - | - | - |